Catalyst Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Catalyst Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.08M	Hold	192,000	–	–	0.05%	89
2026 Q1	$3.56M	Hold	192,000	–	–	0.07%	79
2025 Q4	$2.99M	Buy	192,000 +7,000	+4%	+$100K	0.06%	94
2025 Q3	$2.71M	Buy	185,000 +4,000	+2%	+$59.4K	0.05%	101
2025 Q2	$2.8M	Hold	181,000	–	–	0.06%	96
2025 Q1	$2.69M	Buy	181,000 +3,000	+2%	+$42K	0.06%	97
2024 Q4	$2.36M	Hold	178,000	–	–	0.05%	104
2024 Q3	$2.53M	Buy	178,000 +12,000	+7%	+$170K	0.06%	102
2024 Q2	$2.15M	Sell	166,000 -3,000	-2%	-$39.7K	0.05%	109
2024 Q1	$2.35M	Hold	169,000	–	–	0.06%	109
2023 Q4	$2.41M	Buy	+169,000	New	+$2.4M	0.06%	103
2021 Q4	–	Sell	-126,000	Closed	-$2.06M	–	424
2021 Q3	$2.06M	Hold	126,000	–	–	0.1%	140
2021 Q2	$2.12M	Buy	126,000 +13,700	+12%	+$233K	0.1%	128
2021 Q1	$2.05M	Buy	112,300 +24,000	+27%	+$432K	0.11%	110
2020 Q4	$1.61M	Buy	88,300 +10,300	+13%	+$181K	0.09%	122
2020 Q3	$1.39M	Buy	78,000 +40,000	+105%	+$728K	0.08%	126
2020 Q2	$681K	Buy	+38,000	New	+$682K	0.04%	162
2019 Q4	–	Sell	-5,215	Closed	-$90K	–	408
2019 Q3	$90K	Buy	5,215 +1,656	+47%	+$28.6K	﹤0.01%	238
2019 Q2	$63K	Sell	3,559 -963	-21%	-$17.5K	﹤0.01%	216
2019 Q1	$92K	Buy	+4,522	New	+$91K	﹤0.01%	218

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Catalyst Capital Advisors's TAK Position: Q2 2026 in Review

Catalyst Capital Advisors held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 192,000 shares worth $3.08M. The position accounts for 0.05% of the portfolio, ranked #89.

Catalyst Capital Advisors first reported a position in TAK in Q1 2019 and has held it in 20 quarters since. The position peaked at $3.56M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Catalyst Capital Advisors held 192,000 shares of Takeda Pharmaceutical worth $3.08M as of Q2 2026.
Catalyst Capital Advisors left its Takeda Pharmaceutical share count unchanged in Q2 2026.
Takeda Pharmaceutical made up 0.05% of Catalyst Capital Advisors's portfolio in Q2 2026, its #89 holding.
Catalyst Capital Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 20 quarters since.
Catalyst Capital Advisors's Takeda Pharmaceutical position peaked at $3.56M in Q1 2026.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.